Author | Study design | Patients, n | Delay | Primary outcome | SAE definition | Follow-up | Mortality, % | RVD definition | RVD, % | HI, n | Thrombolysis, n (%) | Age, years | Male, % | CHF, % | COPD, % |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TTE | |||||||||||||||
Grifoni, et al. [7] | Prosp | 162 (209a ) | <1 hour | Death | Clinical worsening, death | Hospital | 4 | 1 in A1, A2, B, G, H1 | 40 | 0 (47 excluded) | 10 (5%) | 65 ± 15 | 40 | 14 | 25 |
Kostrubiec, et al. [8] | Prosp | 98 | <24 hours | Death | Death, vasopressor, thrombolysis, CPR | 40 days | 13 | A9 + C or G + H1 | 60 | 0 | 5 (5%) | 63 ± 18 | 38 | 17 | 7 |
Pieralli, et al. [9] | Prosp | 61 | <1 hour | Death | Death, PE recurrence, HI | Hospital | 6.5 | 1 in A1, A2, B, C, G, H2 | 57 | 0 | 6 (10%) | 75 ± 14 | 26 | 0 | 10 |
Jimenez, et al. [10] | Prosp | 214 | <48 hours | Death | Not studied | 30 days | 3 | 1 in A1, A2,C,F | 40 | 0 | NA | NA | 49 | 11.7 | 13 |
Logeart, et al. [11] | Prosp | 67 | <19 hours | Death | Death, thrombolysis, HI | Hospital | 1.5 | 2 in A3, B, C, D2, F | 54 | 0 | 6 (9%) | 64 | 60 | 0 | NA |
Zhu, et al. [12] | Prosp | 468 (520a ) | NA | SAE | Death, thrombolysis, CPR, MV, embolectomy | 14 days | 1 | 2 in : A2 or A6, C, D3, F | 42 | 0 (52 excluded) | NA | 57 ± 14 | 62 | NA | 8 |
Gallota, et al. [13] | Prosp | 90 | <1 hour | SAE | Death, HI | Hospital | 13 | 1 in A5, B | 72 | 0 | NA | 67 ± 18 | 28 | 44 | 11 |
Palmieri, et al. [14] | Prosp | 89 | Admission | SAE | Death, HI | Hospital | 13.5 | A4 + B + C | 54 | 0 | NA | 63 ± 15 | 27 | NA | 10 |
Spiral CT | |||||||||||||||
van der Meer, et al. [15] | Retro | 120 | NA | Death (PE) | Not studied | 3 months | 15 | dRV/dLV >1 | 57.5 | 0 | 0 | 59 ± 18 | 46 | NA | NA |
Moroni [16] | Retro | 226 | NA | Death | Not studied | 3 months | 10.6 | dRV/dLV >1 | 35 | 0 | 0 | 67 ± 17 | 50 | 14 | 6.5 |
Stein, et al. [17] | Retro | 157 | NA | Death | Not studied | 30 days | 2.5 | dRV/dLV >1 | 50 | 0 | 2 (1.3%) | 56 ± 17 | 41 | 0 | 0 |
NT-proBNP | |||||||||||||||
Kostrubiec, et al. [8] | Prosp | 100 | Admission | Death | Death, thrombolysis, CPR, embolectomy, vasopressors | 40 days | 15 | >600 pg/mL | 39 | 0 | 5 | 62 ± 18 | 35 | 17 | 7 |
Pruszczyk, et al. [18] | Prosp | 70 | Admission | Death | Death, thrombolysis, CPR, embolectomy, vasopressors | Hospital | 15.7 | NA | 83.5 | 0 (9 excluded) | 8 | 63 ± 17 | 37 | NA | NA |
Vuilleumier, et al. [21] | Prosp | 146 | Admission | Death | - | 3 months | 3.4 | 300 pg/mL | 60 | 0 | 0 | NA | 42 | NA | 5 |
BNP | |||||||||||||||
Pieralli, et al. [9] | Prosp | 61 | Admission (<1 hour) | Death | Death, HI, PE recurrence | Hospital | 6.5 | >100 pg/mL | 70 | 0 | 6 | 75 ± 14 | 26 | Excluded | 10 |
Logeart, et al. [11] | Prosp | 67 | Admission | Death | Death, thrombolysis, CPR, vasopressors | Hospital | 1.5 | >527 pg/mL | 67 | 0 | 6 | 64 ± 16 | 60 | Excluded | NA |
ten Wolde, et al. [19] | Prosp | 110 | Admission | Death | Not studied | 3 months | 8.2 | >21.7 pmol/L | 33 | 0 | NA | 58 ± 18 | NA | NA | NA |
Tulevski, et al. [20] | Prosp | 28 | Admission (<1 hour) | Death | Not studied | 90 days | 7.1 | >10 pmol/L | 50 | 0 | NA | 53 ± 18 | 43 | Excluded | 0 |